

This listing of claims will replace all prior versions, and listing, of claims in the application.

Listing of Claims:

1. (Currently amended) A method of screening drug candidates comprising:
a) providing a B cell that expresses an one or more expression profile genes selected from the group ~~selected~~ consisting of Egr-1, Egr-2, Nur77, c-myc, MIP-1a (macrophage inflammatory protein-1-alpha), MIP-1b (macrophage inflammatory protein-1-alpha), BL34 (B-cell activation protein BL34), gfi-1, NAB2 (NGFI-A binding protein 2), neurogranin, SLAP (Src-like adapter protein), A1, E2/20K, SATB1, Cctq (cytosolic chaperone containing TCP-1, theta subunit), kappa V, pcp-4, TGIF, CD83 (CD83 antigen precursor), ApoE (apolipoprotein E), Aeg-2 (acidic epididymal glycoprotein-like protein-2), CD72, cyclin D2, Ick, MEF-2C (myocyte-specific enhancer factor 2C), bmk (B cell/myeloid kinase), IgD (immunoglobulin D), Evi-2 (ecotropic viral integration site 2), vimentin, CD36, c-fes, c-fos, TRAP (acid phosphatase type 5), hIP30 (gamma-interferon-inducible protein precursor), Ly6E.1, LRG-21, Fos B, gadd153, mafK, Ah-R (arylhydrocarbon receptor), C/EBP beta (CCAAT/enhancer binding protein), EZF (epithelial zinc-finger protein), TIS7, TIS11, TIS11b, LSIRF (lymphoid-specific interferon regulator factor), MKP1, PAC-1 (musculus protein tyrosine phosphatase PAC-1), PEP (protein tyrosine phosphatase), MacMARCKS, SNK (serum inducible kinase), Stra13, kir/gem, EB12, IL1-R2 (type II interleukin-1 receptor), MyD116 (myeloid differentiation primary response), RP105 (leucine-rich repeat protein 105), uPAR (urokinase-type plasminogen activator receptor), 4F2, hRab30, Id3, BKLf, LKLF (Kruppel-like factor LKLF), EFP (estrogen-responsive finger protein), bcl-3, caspase 2, GILZ (glucocorticoid-induced leucine zipper), hIFI-204, hRhoH (RHO-related GTP-binding protein), TRAF5, LT-beta (musculus lymphotoxin-beta), IFNg-RII (interferon gamma receptor second chain), gadd45, CDC47, NAG (N-acetylglucosaminyltransferase), scd2 (stearoyl-CoA desaturase), kappa 0 ig (kappa immunoglobulin germ line gene), iap38 (immunity associated protein 38), G7e, B29, carb anh II (carbonic anhydrase II) and SCD2 Stat1;

Application No.: 09/747,760
Amendment dated March 4, 2003
Reply to Office Action of November 4, 2002

2. (Currently amended) A The method according to claim 1 wherein ~~the~~
determining comprises comparing the level of expression of the one or more expression profile
genes in the absence of the drug candidate to the level of expression of the same genes in the
presence of the drug candidate.

3-21. (Withdrawn)